This story was originally published April 14.
Agilent Technologies said last week that large-scale Chinese genome center BGI will use several of its products as part of its next-generation sequencing process.
Specifically, BGI will use Agilent's SureSelect solution-based target enrichment product for targeted sequencing in human genetic studies, particularly in cancer genome projects.
BGI researchers worked with Agilent's China Life Science group and Agilent R&D to test and validate SureSelect.
In addition, BGI is adopting Agilent's Bravo automated liquid-handling platform for next-generation sequencing sample preparation, and the company's 2100 Bioanalyzer to analyze DNA libraries prior to sequencing.
According to its website, BGI currently has 28 Illumina Genome Analyzers, 10 Illumina HiSeq 2000, and two Applied Biosystems SOLiD systems installed. Earlier this year, BGI ordered 128 Illumina HiSeq 2000 sequencers, which are expected to be delivered by the end of this year.